Palvella COO sells 4,302 shares at $150.62–$156.77
PALVELLA THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PALVELLA THERAPEUTICS, INC. (PVLA) reported that Chief Operating Officer Kathleen Goin exercised stock options covering 4,302 shares of common stock on August 19, 2026, at exercise prices of $7.14 and $9.08 per share, and sold 4,302 shares in multiple open-market transactions at prices between $150.62 and $156.77 per share. These trades were executed under a Rule 10b5-1 trading plan adopted on August 19, 2025, and the exercised options were fully vested.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,302 shares ($620K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Goin Kathleen
Role
Chief Operating Officer
Sold
4,302 shs ($655K)
Approx. gross sale proceeds
$655K
Approx. exercise cost
$35K
Approx. pre-tax spread
$620K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F6 | 2,154 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F6 | 2,148 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,154 | $7.14 | $15K |
| Exercise | Common Stock F1 | 2,148 | $9.08 | $20K |
| Sale | Common Stock F1, F2 | 1,500 | $151.39 | $227K |
| Sale | Common Stock F1, F3 | 1,998 | $151.7979 | $303K |
| Sale | Common Stock F1, F4 | 400 | $152.9975 | $61K |
| Sale | Common Stock F1, F5 | 102 | $155.5898 | $16K |
| Sale | Common Stock F1 | 302 | $156.77 | $47K |
Holdings After Transaction:
Stock Option (Right to Buy) — 8,615 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (6)
- F1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.62 to $151.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.665 to $152.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.93 to $153.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.58 to $155.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F6. The stock option is fully vested.
Key Figures
Options exercised (shares): 4,302 shares
Exercise price per share: $7.14 and $9.08
Shares sold: 4,302 shares
+3 more
6 metrics
Options exercised (shares)
4,302 shares
Total underlying common shares from option exercises on August 19, 2026
Exercise price per share
$7.14 and $9.08
Stock options exercised for 2,154 and 2,148 shares, respectively
Shares sold
4,302 shares
Common stock sold in multiple transactions on August 19, 2026
Sale price range
$150.62–$156.77 per share
Price range across reported open-market sales with weighted averages
10b5-1 plan adoption date
August 19, 2025
Date Kathleen Goin adopted the Rule 10b5-1 trading plan
Option expiration dates
October 29, 2029 and October 14, 2030
Expiration dates for the exercised stock options
Key Terms
Rule 10b5-1 trading plan, weighted average price, material non-public information, Insider Trading Policy, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions ... were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
material non-public information regulatory
"at a time when the Reporting Person was not in possession of material non-public information"
Material non-public information is important news about a company that hasn't been shared with the public yet, like a secret that could affect its stock price. Using this inside information to buy or sell stocks is unfair and illegal because it gives someone an unfair advantage over others who don’t have the same info.
Insider Trading Policy regulatory
"and was reviewed and approved in accordance with the Issuer's Insider Trading Policy"
A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did PVLA’s COO Kathleen Goin report in this Form 4?
Kathleen Goin exercised stock options for 4,302 shares of Palvella Therapeutics common stock and sold 4,302 shares in multiple open-market transactions on August 19, 2026. The transactions involved both option exercises and subsequent sales of common stock.
What stock options did Kathleen Goin exercise in Palvella Therapeutics (PVLA)?
She exercised options for 2,154 shares at an exercise price of $7.14 per share, expiring October 29, 2029, and 2,148 shares at an exercise price of $9.08 per share, expiring October 14, 2030. The options were reported as fully vested.
Were Kathleen Goin’s PVLA trades under a Rule 10b5-1 trading plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025, during an open trading window and in accordance with Palvella Therapeutics’ Insider Trading Policy.
Did the Form 4 for PVLA indicate weighted average sale prices?
Yes. Several sale transactions report a weighted average price, with detailed price ranges: for example, $150.62–$151.445, $151.665–$152.47, $152.93–$153.20, and $155.58–$155.59, with an additional sale at $156.77 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates